ADMA Biologics (ADMA) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $119.8M, up 78% year-over-year, with GAAP net income of $35.9M, a 1,300% increase, driven by strong demand for immunoglobulin products, especially ASCENIV.

• Adjusted EBITDA reached $45.4M, up 256% year-over-year, with sequential growth and operational improvements.

• Expanded manufacturing capacity and supply chain enhancements at the Boca Facility support higher production and revenue targets for 2024 and 2025.

• Plasma collection network now includes ten FDA-licensed centers, providing self-sufficiency in plasma supply and additional revenue from third-party plasma sales.

• Appointed KPMG as new independent auditor and joined the S&P SmallCap 600 Index, enhancing governance and market visibility.

Financial highlights

• Q3 2024 revenue: $119.8M, up 78% year-over-year; nine months revenue: $308.9M, up 68%.

• Q3 2024 net income: $35.9M vs. $2.6M in Q3 2023; nine months net income: $85.8M vs. $10.6M net loss in 2023.

• Gross margin improved to 50% in Q3 2024 (from 37% in Q3 2023); nine months gross margin: 50.6%.

• Adjusted EBITDA for Q3 2024: $45.4M, up from $12.7M in Q3 2023; nine months: $116.3M.

• Operating cash flow for Q3 2024 was $25M; working capital at September 30, 2024: $273.3M.

Outlook and guidance

• 2024 revenue guidance raised to exceed $415M, with adjusted EBITDA projected to surpass $160M and GAAP net income over $120M.

• 2025 revenue guidance raised to exceed $465M, with adjusted EBITDA over $215M and GAAP net income above $165M.

• Significant margin expansion expected in 2025 and 2026, driven by yield enhancement and revenue mix shift toward ASCENIV.

• Yield enhancement benefits not yet included in 2025 guidance; major impact expected from the second half of 2025 onward.

• Cash, cash equivalents, and accounts receivable, along with projected cash flow, expected to fund operations through at least Q4 2025.